Keyword: Kala Pharmaceuticals
Celgene brings on Keytruda R&D exec Alise Reicin in shake-up; IBM Watson Health chief Deborah DiSanzo steps down; and AbbVie CFO Bill Chase to retire.
Shire’s Steven Zhang, M.D., Ph.D., joined Kala Pharmaceuticals to lead its medical affairs work as it begins transitioning to the commercial stage.
Check out the rest of Thursday's news of note.
Kala Pharmaceuticals has filed to list on Nasdaq to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.
The brainchild of the ubiquitous MIT Professor Bob Langer and some former students, Kala moved from a launch with preclinical animal data to late-stage testing in three years. An IPO may come next.